Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;46(10):2178-2189.
doi: 10.1007/s00259-019-04397-2. Epub 2019 Jul 1.

Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies

Heiko Kroth  1 , Felix Oden  2 , Jerome Molette  1 , Hanno Schieferstein  3   4 , Francesca Capotosti  1 , Andre Mueller  2 , Mathias Berndt  2 , Heribert Schmitt-Willich  2 , Vincent Darmency  1 , Emanuele Gabellieri  1 , Cédric Boudou  1 , Tanja Juergens  1 , Yvan Varisco  1 , Efthymia Vokali  1 , David T Hickman  1 , Gilles Tamagnan  5   6 , Andrea Pfeifer  1 , Ludger Dinkelborg  2 , Andreas Muhs  1 , Andrew Stephens  7
Affiliations

Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies

Heiko Kroth et al. Eur J Nucl Med Mol Imaging. 2019 Sep.

Abstract

Purpose: Tau deposition is a key pathological feature of Alzheimer's disease (AD) and other neurodegenerative disorders. The spreading of tau neurofibrillary tangles across defined brain regions corresponds to the observed level of cognitive decline in AD. Positron-emission tomography (PET) has proved to be an important tool for the detection of amyloid-beta (Aβ) aggregates in the brain, and is currently being explored for detection of pathological misfolded tau in AD and other non-AD tauopathies. Several PET tracers targeting tau deposits have been discovered and tested in humans. Limitations have been reported, especially regarding their selectivity.

Methods: In our screening campaign we identified pyrrolo[2,3-b:4,5-c']dipyridine core structures with high affinity for aggregated tau. Further characterization showed that compounds containing this moiety had significantly reduced monoamine oxidase A (MAO-A) binding compared to pyrido[4,3-b]indole derivatives such as AV-1451.

Results: Here we present preclinical data of all ten fluoropyridine regioisomers attached to the pyrrolo[2,3-b:4,5-c']dipyridine scaffold, revealing compounds 4 and 7 with superior properties. The lead candidate [18F]PI-2620 (compound 7) displayed high affinity for tau deposits in AD brain homogenate competition assays. Specific binding to pathological misfolded tau was further demonstrated by autoradiography on AD brain sections (Braak I-VI), Pick's disease and progressive supranuclear palsy (PSP) pathology, whereas no specific tracer binding was detected on brain slices from non-demented donors. In addition to its high affinity binding to tau aggregates, the compound showed excellent selectivity with no off-target binding to Aβ or MAO-A/B. Good brain uptake and fast washout were observed in healthy mice and non-human primates.

Conclusions: Therefore, [18F]PI-2620 was selected for clinical validation.

Keywords: AD; Alzheimer’s disease; Fluorine-18; PET; PET tracer; PI-2620; Positron-emission tomography; Tau; Tauopathies.

PubMed Disclaimer

Conflict of interest statement

• Heiko Kroth is an employee of AC Immune and holds shares of AC Immune.

• Felix Oden is an employee of LMI.

• Jerome Molette is an employee of AC Immune and holds shares of AC Immune.

• Hanno Schieferstein has no conflict of interest.

• Francesca Capotosti is an employee of AC Immune.

• Andre Mueller is an employee of LMI.

• Mathias Berndt is an employee of LMI.

• Heribert Schmitt-Willich is an employee of LMI.

• Vincent Darmency is an employee of AC Immune.

• Emanuele Gabellieri is an employee of AC Immune and holds shares of AC Immune.

• Cédric Boudou is an employee of AC Immune and holds shares of AC Immune.

• Tanja Juergens is an employee of AC Immune.

• Yvan Varisco is an employee of AC Immune and holds shares of AC Immune.

• Efthymia Vokali is an employee of AC Immune.

• David Tadeusz Hickman is an employee of AC Immune and holds shares of AC Immune.

• Gilles Tamagnan has no conflict of interest.

• Andrea Pfeifer is an employee of AC Immune and holds shares of AC Immune.

• Ludger Dinkelborg is an employee of LMI.

• Andreas Muhs was an employee of AC Immune and holds shares of AC Immune.

• Andrew Wills Stephens is an employee of LMI.

Figures

Fig. 1
Fig. 1
Structures of 18F-labeled tau PET tracers
Fig. 2
Fig. 2
Design of fluoropyridine regioisomers. Data from our screening campaign revealed that both pyrrolo[2,3-b:4,5-c’]dipyridine and pyrido[4,3-b]indole core structures exhibit high affinity for tau, but significantly reduced MAO-A binding was measured for pyrrolo[2,3-b:4,5-c’]dipyridine core structures only, providing the rationale to investigate all ten fluoropyridine regioisomers in more detail. Compound numbering: 1 (AV-1451), 2, 3 (RO6958948), 4, 5, 6, 7 (PI-2620), 8, 9, 10, 11 and 12
Fig. 3
Fig. 3
Time activity curves (SUV) for [18F]PI-2620 ([18F]7) in brain regions at baseline in a rhesus macaque (a). SUV images at three different time intervals p.i. (b)
Fig. 4
Fig. 4
Assessment of specific binding of PI-2620 (7) to tau aggregates in human AD brain sections. a [18F]PI-2620 was tested in ARG on AD patient-derived brain slices staged Braak I, III, and V as well as a non-demented control (NDC). Non-specific binding (NSB) was determined adding 5 μM unlabeled PI-2620. Specific ARG signal correlates with IHC staining on adjacent slices using AT8 antibody. b Micro-ARG in entorhinal cortex brain sections from an AD donor with [3H]PI-2620 revealed accumulation of silver grains on NFT which is blocked by adding 5 μM unlabeled PI-2620. Thioflavin S staining on adjacent sections correlated with the specific micro-ARG signal. TOTB, total binding; NSB, non-specific binding
Fig. 5
Fig. 5
Assessment of specific binding of PI-2620 (7) to tau aggregates in human PSP brain sections. a ARG of [18F]PI-2620 on PSP patient-derived brain slices. Specific ARG signal correlated with IHC staining on adjacent section using the 4R-specific ET3 antibody (kindly provided by Peter Davies, Northwell, USA). b Micro-ARG signal on PSP patient-derived brain sections correlated with IHC staining on the same sections using the MC1 antibody
See this image and copyright information in PMC

References

    1. Alzheimer's A. Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332–384. doi: 10.1016/j.jalz.2015.02.003. - DOI - PubMed
    1. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387–398. doi: 10.1038/nrd2896. - DOI - PubMed
    1. Ariza M, et al. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58(11):4365–4382. doi: 10.1021/jm5017544. - DOI - PubMed
    1. Heurling K, et al. Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43(2):362–373. doi: 10.1007/s00259-015-3208-1. - DOI - PubMed
    1. Sabbagh MN, et al. Histopathology and Florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease. J Alzheimers Dis. 2017;56(2):441–446. doi: 10.3233/JAD-160821. - DOI - PubMed

MeSH terms